FRM
AMLX icon

Fox Run Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Fox Run Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$805K Buy
+44,817
New +$693K 0.13% 269
2026
Q1 		– Sell
-35,409
Closed -$428K – 883
2025
Q4 		$428K Buy
+35,409
New +$481K 0.07% 561
2025
Q1 		– Sell
-11,788
Closed -$44.6K – 893
2024
Q4 		$44.6K Buy
+11,788
New +$55.5K 0.01% 828
2024
Q1 		– Sell
-22,007
Closed -$324K – 735
2023
Q4 		$324K Buy
22,007
+5,022
+30% +$77K 0.08% 467
2023
Q3 		$311K Sell
16,985
-1,007
-6% -$21.3K 0.09% 431
2023
Q2 		$388K Buy
17,992
+5,494
+44% +$148K 0.11% 356
2023
Q1 		$367K Buy
+12,498
New +$434K 0.12% 337

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Fox Run Management's AMLX Position: Q2 2026 in Review

Fox Run Management opened a new position in Amylyx Pharmaceuticals (AMLX) in Q2 2026: 44,817 shares worth $805K. The stake represents 0.13% of the portfolio and ranks #269 among its holdings. This is a return to the name: Fox Run Management previously reported a position in AMLX as recently as Q4 2025.

Fox Run Management first reported a position in AMLX in Q1 2023 and has held it in 7 quarters since. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Fox Run Management held 44,817 shares of Amylyx Pharmaceuticals worth $805K as of Q2 2026.
  • Amylyx Pharmaceuticals was a new Fox Run Management position in Q2 2026.
  • Amylyx Pharmaceuticals made up 0.13% of Fox Run Management's portfolio in Q2 2026, its #269 holding.
  • Fox Run Management first reported a position in Amylyx Pharmaceuticals in Q1 2023 and has held it in 7 quarters since.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.